Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)

Guntram Schernthaner

doi:10.4093/dmj.2021.0081

Articles

Page Path: HOME > Diabetes Metab J > Volume 45(4); 2021 > Article

Letter Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9): Guntram Schernthaner; Diabetes & Metabolism Journal 2021;45(4):615-616.
DOI: https://doi.org/10.4093/dmj.2021.0081
Published online: July 30, 2021

4,265 Views
72 Download
2 Web of Science
2 Crossref
4 Scopus

Department of Medicine, Medical University of Vienna, Vienna, Austria

Corresponding author: Guntram Schernthaner

Department of Medicine, Medical University of Vienna, 1180 Währinger Gürtel, Vienna, Austria E-mail: guntram.schernthaner@meduniwien.ac.at

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

Full Article

Download PDF

NOTES
REFERENCES
About this article

See the article "Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19" on page 251.

People with diabetes are at increased risk of severe coronavirus disease 2019 (COVID-19) complications, and COVID-19-related mortality in this population is two to three times higher than that in people without diabetes [1]. Glucose-lowering drugs used in the treatment of patients with diabetes might have significant effects on COVID-19 pathophysiology, potentially affecting the risk of progression to severe disease and mortality. Rhee et al. [2] reported data suggesting that dipeptidyl peptidase-4 inhibitors (DPP-4is) are significantly associated with a better clinical outcome in patients with COVID-19. The unadjusted odds ratio (OR) of severe/lethal cases among DPP-4i users was 0.77 (95% confidence interval [CI], 0.35 to 1.68); after some adjustment, the OR changed to 0.36 (95% CI, 0.13 to 0.97). This enourmous discrepancy—between the unadjusted and adjusted ORs—is difficult to understand.

The authors have compared relatively small cohorts not matched for critical factors. While DPP-4i users (n=263) and non-DPP-4i users (n=569) had a similar baseline risk for some mortality-linked comorbidities (e.g., cardiovascular disease, 26% vs. 28%; chronic kidney disease, 16% vs. 11%; and cancer, 18% vs. 24%), no information was given about heart failure, which is now one of the leading risk factors for mortality in diabetic patients. By contrast, treatment quality was extremely different and significantly better in the group receiving DPP-4i compared with non-users (metformin, 82% vs. 15%; statins, 61% vs. 29%; renin-angiotensin system blockade, 49% vs. 24%; and angiotensin receptor blocker inhibitors, 47% vs. 23%). Thus, it is extremely likely that the use of metformin and cardioprotective drugs have strongly influenced relative clinical outcomes for patients using DPP-4i. Indeed, a recent meta-analysis [3] of five studies encompassing 8,121 patients with diabetes who were admitted to hospital for COVID-19 showed a significantly reduced mortality rate associated with the use of metformin (OR, 0.62; 95% CI, 0.43 to 0.89). In addition, a recent population-based cohort study from Korea [4] showed that the use of statins was associated with lower mortality in patients with COVID-19 (hazard ratio [HR], 0.64; 95% CI, 0.42 to 0.95).

Very recently, several large population studies were published analyzing the effect of different glucose-lowering drugs on mortality in patients with diabetes during the COVID-19 pandemic (Table 1). In the UK, the pre-infection prescription of glucose-lowering therapies and risk of COVID-19 mortality was analysed in 2.85 million people with type 2 diabetes mellitus [5]. Overall, a COVID-19-related death occurred in 13,479 (0.5%) subjects. Metformin, sodium glucose co-transporter 2 (SGLT2) inhibitors, and sulfonylureas were associated with reduced risks of COVID-19-related mortality, whereas insulin and DPP-4is were associated with increases in risk; neutral results were found for glucagon-like peptide-1 (GLP-1) receptor agonists and thiazolidinediones. Interestingly, the use of SGLT2 inhibitors (HR, 0.82; 95% CI, 0.74 to 0.91) compared with DPP-4is (HR, 1.07; 95% CI, 1.01 to 1.13) was associated with significantly lower COVID-19 mortality risk [2]. However, as expected from treatment recommendations [6,7], patients using DPP-4i in the UK study were older and were more likely to have chronic kidney disease [5].

In a Danish population-based study [8], the impact of current use of novel glucose-lowering drugs on COVID-19 was studied and relative risks (RR) were calculated after applying propensity score weighted methods to control for confounding. Current users of GLP-1 receptor agonists had an adjusted RR of 0.89 (95% CI, 0.34 to 2.33), while users of DPP-4i had an adjusted RR of 2.42 (95% CI, 0.99 to 5.89), for 30-day mortality compared with SGLT2 inhibitor use. In the French population-based Coronavirus SARS-CoV-2 and Diabetes Outcomes (CORONADO) study [9], the use of metformin was associated with a significantly reduced mortality in diabetic patients with COVID-19 (OR, 0.63; 95% CI, 0.52 to 0.77), whereas the use of DPP-4i had a neutral effect (OR, 0.83; 95% CI, 0.65 to 1.05). In a recent meta-analysis of seven studies [10], death occurred in 111 of 612 (18%) patients treated with DPP-4i and in 335 of 1,703 (20%) patients treated with other glucose-lowering medication, again suggesting a neutral effect (RR, 0.81; 95% CI, 0.57 to 1.15).

Several randomized controlled trials (NCT04365517, NCT04371978, and NCT04341935) are being conducted with DPP-4is in patients with type 2 diabetes mellitus and COVID-19. Until we have evidence from prospective, randomized studies such as these, data on the effectiveness or safety of DPP-4i in patients with COVID-19 should be interpreted with caution.

NOTES

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Table 1.

Effect of DPP-4is on COVID-19 related mortality/severe outcome in population based studies

Country	No. of patients using DPP-4i	No. of patients not using DPP-4i	HR (95% CI)
UK (5)	479,555	2,371,910	1.07 (1.01–1.13)^a
France (9)	285	1,032	0.85 (0.55–1.32)^a
Denmark (8)	575	540^c	2.42 (0.99–5.88)^a
Korea (3)	263	569	0.36 (0.13–0.97)^b

DPP-4i, dipeptidyl peptidase-4 inhibitor; COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval.

^a Mortality,

^b Severe/lethal cases,

^c Patients in the control arm received sodium glucose co-transporter 2 inhibitors.

REFERENCES

1. Schernthaner G. Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes? Lancet Diabetes Endocrinol 2021;9:251-2.Article PubMed PMC
2. Rhee SY, Lee J, Nam H, Kyoung DS, Shin DW, Kim DJ. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. Diabetes Metab J 2021;45:251-9.Article PubMed PMC PDF
3. Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. J Med Virol 2021;93:695-7.Article PubMed PDF
4. Lee HY, Ahn J, Park J, Kang CK, Won SH, Kim DW, et al. Beneficial effect of statins in COVID-19-related outcomes-brief report: a national population-based cohort study. Arterioscler Thromb Vasc Biol 2021;41:e175-82.PubMed PMC
5. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 2021;9:293-303.Article PubMed PMC
6. Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab 2014;16:1078-86.Article PubMed
7. Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013. Diabetes Obes Metab 2016;18:607-14.Article PubMed PDF
8. Israelsen SB, Pottegard A, Sandholdt H, Madsbad S, Thomsen RW, Benfield T. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes Metab 2021;23:1397-401.PubMed PMC
9. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-15.Article PubMed PMC PDF
10. Bonora BM, Avogaro A, Fadini GP. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest 2021;44:1379-86.Article PubMed PMC PDF

Figure & Data

References

Citations

Citations to this article as recorded by

The risk of common hypoglycemic and antihypertensive medications and COVID-19: A 2-sample Mendelian randomization study
Ya Wang, Kai Li, Jiaxing Zeng, Shunyu Lu, Wangsheng Deng
Medicine.2024; 103(6): e36423. CrossRef
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný, Guntram Schernthaner
Cardiovascular Diabetology.2021;[Epub] CrossRef

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)

Diabetes Metab J. 2021;45(4):615-616. Published online July 30, 2021

DOI: https://doi.org/10.4093/dmj.2021.0081

XML Download

Related articles

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)

Country	No. of patients using DPP-4i	No. of patients not using DPP-4i	HR (95% CI)
UK (5)	479,555	2,371,910	1.07 (1.01–1.13)^a
France (9)	285	1,032	0.85 (0.55–1.32)^a
Denmark (8)	575	540^c	2.42 (0.99–5.88)^a
Korea (3)	263	569	0.36 (0.13–0.97)^b

Table 1. Effect of DPP-4is on COVID-19 related mortality/severe outcome in population based studies

DPP-4i, dipeptidyl peptidase-4 inhibitor; COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval.

Mortality,

Severe/lethal cases,

Patients in the control arm received sodium glucose co-transporter 2 inhibitors.

Table 1.

About this article

Schernthaner G. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9). Diabetes Metab J. 2021;45(4):615-616.

DOI: https://doi.org/10.4093/dmj.2021.0081.

Download citation ↓